Regeneron Announces Positive Topline Phase 2 Data with Anti -C5 Antibody Pozelimab in Patients with a Rare Blood Disorder

(STL.News) – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced topline data from the pozelimab (REGN3918) Phase…

Regeneron Announces Upcoming Investor Conference Presentations

(STL.News) – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations as follows: Guggenheim Healthcare Talks…

Regeneron Colleagues Support 150 Community Organizations During Third Annual Day For Doing Good

(STL.News) – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today celebrates its third annual Day for Doing Good,…